Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K+ currents and action potentials

British Journal of Pharmacology

Volumn 131, Issue 2, 2000, Pages 245-254

  Jones, Stephen E ^a   Shuba, Lesya M ^a   Zhabyeyev, Pavel ^a   McCullough, John R ^b   McDonald, Terence F ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b SUNOVION PHARMACEUTICALS INC   (United States)

Author keywords

Action potential duration; Calcium current; Cardiac action potentials; Cardiac membrane currents; Papillary muscles; Rate dependence; S Oxybutynin; Terodiline; Ventricular myocytes

Indexed keywords

CALCIUM ION; OXYBUTYNIN; POTASSIUM ION; TERODILINE;

ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; CALCIUM CURRENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SPECIFICITY; ENANTIOMER; GUINEA PIG; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HEART PAPILLARY MUSCLE; HEART VENTRICLE TACHYCARDIA; LONG QT SYNDROME; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; RABBIT; URINE INCONTINENCE;

EID: 0033770382     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703595     Document Type: Article

References (51)

1. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder
2. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children
3. Clinical pharmacology of terodiline
4. + currents in isolated human ventricular myocytes from patients with terminal heart failure
5. Ultra-slow voltage-dependent inactivation of the calcium current in guinea-pig and ferret ventricular myocytes
6. Intravesical oxybutynin for neurogenic bladder dysfunction: Less systemic side effects due to reduced first pass metabolism
7. Nocturnal enuresis and daytime wetting: A multicentric trial with oxybutynin and desmopressin
8. Mechanisms and control of repolarization
9. Torsades de pointes ventricular tachycardia and terodiline
10. Block of delayed rectifier potassium current, I(K), by flecainide and E-4031 in cat ventricular myocytes
11. The prevalence and significance of dependent urinary incontinence
12. A study of the anticholinergic and antispasmodic activity of oxybutynin (Ditropan) on rabbit detrusor
13. Effect of changes in frequency of stimulation upon rabbit ventricular action potential
14. Comparison of potassium currents in rabbit atrial and ventricular cells
15. Separation of the components of the delayed rectifier potassium current using selective blockers of I(Kr) and I(Ks) in guinea-pig isolated ventricular myocytes
16. Mechanism of increased amplitude and duration of the plateau with sudden shortening of diastolic intervals in rabbit ventricular cells
17. Pathophysiology and impact of nocturnal enuresis
18. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers
19. The long QT syndromes: A critical review, new clinical observations and a unifying hypothesis
20. + current by therapeutic concentrations of the antispasmodic agent terodiline
21. Pharmacokinetics and safety of (S)-oxybutynin in normal healthy volunteers
22. Transient outward current and rate dependence of action potential duration in rabbit cardiac ventricular muscle
23. Terodiline: A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence
24. Oxybutynin-a musculotropic antispasmodic drug with moderate anticholinergic action
25. Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled-release tablet
26. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite
27. Action potential prolongation and potassium currents in left-ventricular myocytes isolated from hypertrophied rabbit hearts
28. Torsades de pointes complicating treatment with terodiline
29. Enantiomers of oxybutynin: In vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs
30. Block and modified gating of cardiac calcium channel currents by terodiline
31. Action potentials, ionic currents and cell water in guinea pig ventricular preparations exposed to dimethyl sulfoxide
32. Multiple mechanisms in the long-QT syndrome: Current knowledge, gaps, and future directions
33. Cardiac electro-physiological actions of the histamine HI-receptor antagonists astemizole and terfenadine compared with chlorpheniramine
34. + current. Differential sensitivity to block by class III antiarrhythmic agents
35. + currents
36. Contributions of a transient outward current to repolarization in human atrium
37. Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline
38. Comparison of the antimuscarinic and antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of racemic terodiline
39. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval
40. Age-related changes in cardiac physiology. Can they be postponed or treated by drugs?
41. Incontinence after surgery for benign prostatic hypertrophy: The case for complex approach and treatment
42. Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence
43. Prevalence of urinary incontinence
44. Depressant action of oxybutynin on the contractility of intestinal and urinary tract smooth muscle
45. Pharmacologic options for the overactive bladder
46. Transient outward current in human ventricular myocytes of subepicardial and subendocardial origin
47. Mechanism of the cardiotoxic actions of terfenadine
48. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability
49. 1-receptor occupancy
50. QT-interval prolonging drugs: Mechanisms and clinical relevance of their arrhythmogenic hazards
51. Proarrhythmic effects of antiarrhythmic drugs